Regeneron Signs Two Royalty Agreements With Novartis

Published: 11-Jun-2009

Regeneron to receive royalties on worldwide sales of canakinumab

Regeneron has signed two royalty agreements with Novartis that replaces previous collaboration and license agreement.

Under the first royalty agreement, Regeneron is entitled to receive royalties on worldwide sales of Novartis’ canakinumab (ACZ885), a fully human anti-interleukin-IL1ß antibody, to treat cryopyrin-associated periodic syndrome (CAPS).

According to the second royalty agreement, Novartis is entitled to receive royalties on worldwide sales of a second-generation interleukin-1 Trap, should Regeneron decide to proceed in the development of this Trap.

The agreements replaces 2003 collaboration and license agreement under which Regeneron had the right to opt in to the development and commercialization of Novartis’ interleukin-1 antibody, and Novartis had the right to opt in to the development and commercialization of Regeneron’s second-generation interleukin-1 Trap.

Tell your friend about this article